Antifungal Susceptibility Testing: The Times They Are A-Changing

Rex, 2002, Has antifungal susceptibility testing come of age?, Clin Infect Dis, 35, 982, 10.1086/342384 Pappas, 2016, Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 62, e1, 10.1093/cid/civ1194 Lockhart, 2016, Hot topics in antifungal susceptibility testing: a new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug, Clin Microbiol Newsl, 38, 103, 10.1016/j.clinmicnews.2016.06.001 Lockhart, 2017, Candida auris for the clinical microbiology laboratory: not your grandfather's Candida species, Clin Microbiol Newsl, 39, 99, 10.1016/j.clinmicnews.2017.06.003 Pfaller, 2016, Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates, J Antimicrob Chemother, 71, 2868, 10.1093/jac/dkw214 Pfaller, 2017, CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program, Int J Antimicrob Agents, 50, 352, 10.1016/j.ijantimicag.2017.03.028 Lakota, 2018, Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data, Antimicrob Agents Chemother, 62, 10.1128/AAC.02603-17 Pfaller, 2013, In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods, Antimicrob Agents Chemother, 57, 1065, 10.1128/AAC.01588-12 Pfaller, 2013, Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST), J Antimicrob Chemother, 68, 858, 10.1093/jac/dks466 Pfaller, 2017, Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species, Antimicrob Agents Chemother, 61, 10.1128/AAC.00161-17 Oliver, 2016, F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase, Proc Natl Acad Sci USA, 113, 12809, 10.1073/pnas.1608304113 Buil, 2017, In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates, J Antimicrob Chemother, 72, 2548, 10.1093/jac/dkx177 Wiederhold, 2017, Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans, J Antimicrob Chemother, 72, 1977, 10.1093/jac/dkx065 Biswas, 2018, In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi, Med Mycol, 56, 1050 Miyazaki, 2011, In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds, Antimicrob Agents Chemother, 55, 4652, 10.1128/AAC.00291-11 Pfaller, 2011, In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods, Antimicrob Agents Chemother, 55, 5155, 10.1128/AAC.00570-11 Pfaller, 2011, In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method, Diagn Microbiology Infect Dis, 71, 167, 10.1016/j.diagmicrobio.2011.05.001 Shaw, 2018, In vitro and in vivo evaluation of APX001A/APX001 and other gwt1 inhibitors against cryptococcus, Antimicrob Agents Chemother, 62, 10.1128/AAC.00523-18 Warrilow, 2014, The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme, Antimicrob Agents Chemother, 58, 7121, 10.1128/AAC.03707-14 Wiederhold, 2018, Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus, J Antimicrob Chemother, 73, 404, 10.1093/jac/dkx410 Schell, 2017, Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds, Antimicrob Agents Chemother, 61, 10.1128/AAC.01817-16 Garvey, 2015, VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model, Antimicrob Agents Chemother, 59, 1992, 10.1128/AAC.04902-14 Break, 2018, VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans, J Antimicrob Chemother, 73, 151, 10.1093/jac/dkx352 Arendrup, 2016, In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms, Antimicrob Agents Chemother, 60, 532, 10.1128/AAC.02336-15 Nakamura, 2017, ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833, J Antibiotics, 70, 45, 10.1038/ja.2016.107 Revankar, 1998, Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method, J Clin Microbiol, 36, 153, 10.1128/JCM.36.1.153-156.1998 Arthington-Skaggs, 2000, Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis, Antimicrob Agents Chemother, 44, 2081, 10.1128/AAC.44.8.2081-2085.2000 Rueda, 2017, Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia, Clini Microbiol Infect, 23, 49.e1, 10.1016/j.cmi.2016.09.016 Astvad, 2018, Implications of the EUCAST trailing phenomenon in Candida tropicalis for the in vivo susceptibility in invertebrate and murine models, Antimicrob Agents Chemother, 62, 10.1128/AAC.01624-18 Marcos-Zambrano, 2016, Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates, Med Mycol, 54, 733, 10.1093/mmy/myw033 Castanheira, 2016, Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013), Diagn Microbiology Infect Dis, 85, 200, 10.1016/j.diagmicrobio.2016.02.009 Chamilos, 2007, Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences, Antimicrob Agents Chemother, 51, 2257, 10.1128/AAC.00095-07 Soczo, 2007, In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin, Antimicrob Agents Chemother, 51, 4474, 10.1128/AAC.00880-07 Kordalewska, 2018, Understanding echinocandin resistance in the emerging pathogen Candida auris, Antimicrob Agents Chemother, 62, 10.1128/AAC.00238-18 Dudiuk, 2015, Quick detection of FKS1 mutations responsible for clinical echinocandin resistance in Candida albicans, J Clin Microbiol, 53, 2037, 10.1128/JCM.00398-15 Zhao, 2016, Rapid detection of FKS-associated echinocandin resistance in Candida glabrata, Antimicrob Agents Chemother, 60, 6573, 10.1128/AAC.01574-16